Janssen Pharms Company Profile

What is the competitive landscape for JANSSEN PHARMS

JANSSEN PHARMS has fifty-seven approved drugs.

There are eighteen US patents protecting JANSSEN PHARMS drugs.

There are four hundred and seventy-seven patent family members on JANSSEN PHARMS drugs in fifty-three countries and eighty-seven supplementary protection certificates in eighteen countries.

Summary for Janssen Pharms

International Patents:	477
US Patents:	18
Tradenames:	56
Ingredients:	34
NDAs:	57

Drugs and US Patents for Janssen Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	RISPERDAL	risperidone	TABLET, ORALLY DISINTEGRATING;ORAL	021444-004	Dec 23, 2004		DISCN	Yes	No
Janssen Pharms	INVOKAMET	canagliflozin; metformin hydrochloride	TABLET;ORAL	204353-003	Aug 8, 2014		RX	Yes	No	11,576,894		Y
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-003	Sep 20, 2016		RX	Yes	No
Janssen Pharms	AXERT	almotriptan malate	TABLET;ORAL	021001-002	May 7, 2001		DISCN	Yes	No
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-002	Sep 20, 2016		RX	Yes	No
Janssen Pharms	INVEGA SUSTENNA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	022264-001	Jul 31, 2009		RX	Yes	No	9,439,906

Expired US Patents for Janssen Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharms	PROPULSID	cisapride monohydrate	SUSPENSION;ORAL	020398-001	Sep 15, 1995	4,962,115
Janssen Pharms	CONCERTA	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021121-003	Dec 8, 2000	4,612,008*PED
Janssen Pharms	RISPERDAL CONSTA	risperidone	POWDER;INTRAMUSCULAR	021346-003	Oct 29, 2003	5,965,168*PED
Janssen Pharms	RISPERDAL CONSTA	risperidone	POWDER;INTRAMUSCULAR	021346-002	Oct 29, 2003	5,916,598*PED
Janssen Pharms	DITROPAN XL	oxybutynin chloride	TABLET, EXTENDED RELEASE;ORAL	020897-001	Dec 16, 1998	4,612,008*PED
Janssen Pharms	RISPERDAL	risperidone	TABLET;ORAL	020272-003	Dec 29, 1993	5,158,952*PED

Paragraph IV (Patent) Challenges for JANSSEN PHARMS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Capsules	15 mg and 25 mg		2005-09-07
	Tablets	10 mg, 15 mg, and 20 mg		2015-07-01
	Tablets	4 mg, 8 mg and 12 mg		2005-02-28
	Orally Disintegrating Tablets	3 mg and 4 mg		2005-03-23
	Extended-release Tablets	18 mg, 27 mg, 36 mg and 54 mg		2005-07-19
	Tablets	6.25 mg and 12.5 mg		2005-12-08
	Extended-release Capsules	8 mg		2006-03-02
	Tablets	100 mg and 300 mg		2017-03-29
	Oral Solution	10 mg/mL		2013-05-03
	Tablets	50 mg		2005-09-08
	Transdermal System	0.15 mg/0.02 mg per 24 hours		2007-03-22
	Oral Solution	25 mg/mL		2009-07-30
	Orally Disintegrating Tablets	0.25 mg		2005-04-11
	Extended-release Injectable Suspension	39 mg/0.25 mL,78 mg/0.5 mL,117 mg/0.75 mL,156 mg/mL and234 mg/1.5 mL		2017-11-21
	Extended-release Tablets	18 mg*, 27 mg, 36 mg and 54 mg		2005-07-19
	Tablets	50 mg/500 mg, 50mg/1000 mg, 150mg/500 mg, and150 mg/1000 mg		2017-03-29
	Extended-release Capsules	16 mg and 24 mg		2006-03-11
	Tablets	25 mg, 100 mg and 200 mg		2001-12-26

International Patents for Janssen Pharms Drugs

Country	Patent Number	Estimated Expiration
Japan	2022524008
Spain	2732703
Australia	2004261660
Japan	2008528527
New Zealand	577545
Japan	2023552149

Supplementary Protection Certificates for Janssen Pharms Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2805723	LUC00064	Luxembourg		PRODUCT NAME: CLADRIBINE; AUTHORISATION NUMBER AND DATE: EU/1/17/1212 20170824
1651658	PA2014008	Lithuania		PRODUCT NAME: CANAGLIFOZINUM; REGISTRATION NO/DATE: EU/1/13/884/001 - EU/1/13/884/004, 2013 11 15 EU/1/13/884/005 - EU/1/13/884/008 20131115
1214076	49/2008	Austria		PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON; REGISTRATION NO/DATE: 1-27586 20080612
1261606	PA2008018	Lithuania		PRODUCT NAME: RIVAROXABANUM; REG. NO/DATE: EU/1/07/472/001-008 20080930
0605697	9/2001	Austria		PRODUCT NAME: ALMOTRIPTAN UND SEINE PHARMAZEUTISCH AKZEPTABLEN SALZE; NAT. REGISTRATION NO/DATE: 1-23957, 1-23958 20010131; FIRST REGISTRATION: ES 62877 19991223
1635783	C300653	Netherlands		PRODUCT NAME: FENTANYL IN ELKE DOOR HET BASISOCTROOI BESCHERMDE VERSCHIJNINGSVORM; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100906

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Janssen Biotech
• Janssen Pharma
• Janssen Pharms
• Janssen Prods
• Janssen R And D
• Janssen Res And Dev

Janssen Pharmaceuticals: Market Position, Strengths, and Strategic Insights

Last updated: February 19, 2026

Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, maintains a strong, diversified market presence across multiple therapeutic areas, driven by a portfolio of blockbuster drugs and a robust R&D pipeline. The company's competitive advantage is rooted in its established market leadership in immunology and oncology, alongside significant inroads in neuroscience and cardiovascular health. Strategic focus on biologics and innovative delivery systems, coupled with targeted acquisitions and partnerships, reinforces its position.

What is Janssen's Current Market Position?

Janssen holds a significant position in the global pharmaceutical market, consistently ranking among the top-tier companies by revenue. Its market share is substantial in key therapeutic areas, including oncology, immunology, and neuroscience. The company's revenue streams are diversified, with several products exceeding $5 billion in annual sales.

• Oncology: Janssen is a leader in this segment with key products such as Darzalex (daratumumab) for multiple myeloma, Imbruvica (ibrutinib) for various B-cell malignancies, and Erleada (apalutamide) for prostate cancer. These drugs represent a substantial portion of Janssen's oncology revenue and are supported by ongoing clinical trials for expanded indications.
• Immunology: Stelara (ustekinumab) for psoriasis, psoriatic arthritis, and Crohn's disease, and Tremfya (guselkumab) for plaque psoriasis are significant revenue generators. The company also markets Remicade (infliximab), though its market share is impacted by biosimilar competition.
• Neuroscience: In this area, Janssen has a strong presence with products like Invega Sustenna (paliperidone palmitate) and Risperdal Consta (risperidone) for schizophrenia and bipolar disorder. Spravato (esketamine) nasal spray for treatment-resistant depression represents a more recent, innovative offering.
• Cardiovascular & Metabolic Diseases: Invokana (canagliflozin) and Invokamet (canagliflozin/metformin) for type 2 diabetes have been significant contributors, though facing increasing competition.

The company's global reach extends to major markets in North America, Europe, and Asia-Pacific, with strategic investments in emerging markets to broaden its patient access.

What are Janssen's Key Strengths?

Janssen's strengths lie in its diversified product portfolio, robust R&D capabilities, strong patent protection for key assets, and its integration within the larger Johnson & Johnson ecosystem.

• Diversified Therapeutic Areas: Janssen operates across multiple high-growth therapeutic areas, reducing reliance on any single market segment. This diversification mitigates risk associated with market shifts or competitive pressures in a specific disease category.

  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular & Metabolic Diseases
  • Infectious Diseases & Vaccines
  • Pulmonary Hypertension

• Strong Patent Portfolio: The company holds numerous patents on its key products, providing market exclusivity and substantial revenue protection. For example, Darzalex's primary composition of matter patent is expected to expire in 2029 in the U.S. and later in other regions. Imbruvica has a robust patent life extending into the mid-2030s in key markets. This patent protection is critical for recouping R&D investments and maintaining profitability.

• R&D Pipeline and Innovation: Janssen invests heavily in research and development, focusing on biologics, gene therapy, and novel drug modalities. Its pipeline includes investigational drugs for unmet medical needs in areas like Alzheimer's disease, EGFR-mutated non-small cell lung cancer, and lupus. The company is actively exploring digital health solutions and real-world evidence to enhance drug development and patient outcomes. In Q4 2023, Johnson & Johnson reported R&D expenses of $3.4 billion for its Innovative Medicine segment, which includes Janssen.

• Biologics Expertise: Janssen has demonstrated significant success in developing and commercializing complex biologic therapies, particularly in oncology and immunology. This expertise is a key differentiator, as the manufacturing and regulatory pathways for biologics are more intricate than for small molecules.

• Global Commercial Infrastructure: A well-established global sales and marketing network facilitates efficient product launches and market penetration across diverse geographical regions. This infrastructure is essential for maximizing the commercial potential of its drug portfolio.

• Synergies within Johnson & Johnson: As part of Johnson & Johnson, Janssen benefits from the parent company's financial strength, diversified business segments (MedTech, Consumer Health), and shared expertise in areas such as regulatory affairs and supply chain management. This integration provides operational efficiencies and access to capital for strategic initiatives.

What are the Key Therapeutic Areas of Focus for Janssen?

Janssen's strategic emphasis is on therapeutic areas with significant unmet medical needs and strong growth potential.

• Oncology: This remains a core focus, with continued investment in targeted therapies, immunotherapies, and CAR-T cell therapies. The company aims to expand the utility of its existing oncology portfolio through new indications and combination therapies. Key focus areas include hematologic malignancies and solid tumors.

• Immunology: Janssen is committed to developing advanced treatments for autoimmune and inflammatory diseases. This involves a focus on targeted biologics that modulate specific immune pathways to provide durable and safe relief for patients with conditions such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis.

• Neuroscience: Addressing complex neurological and psychiatric disorders is another priority. Research efforts are directed towards developing novel treatments for conditions like Alzheimer's disease, depression, and schizophrenia, with an emphasis on understanding disease mechanisms and identifying new therapeutic targets.

• Cardiovascular & Metabolic Diseases: While facing generic competition for some legacy products, Janssen continues to innovate in this area, particularly with treatments for type 2 diabetes and associated cardiovascular risks. Future research may explore novel approaches to managing metabolic syndrome and cardiovascular complications.

• Infectious Diseases & Vaccines: This area has seen renewed strategic importance, particularly following the COVID-19 pandemic. Janssen is involved in the development and distribution of vaccines and treatments for infectious diseases, aiming to address global health challenges.

• Pulmonary Hypertension: Janssen has a dedicated focus on developing innovative treatments for pulmonary hypertension, a rare and life-threatening condition. This includes both pharmacological and potentially device-based solutions.

What are the Key Competitive Threats Facing Janssen?

Janssen faces significant competitive pressures from both originator pharmaceutical companies and the growing biosimilar and generic markets.

• Biosimilar Competition: The entry of biosimilars for key biologics, such as Remicade (infliximab), directly impacts Janssen's revenue and market share in immunology. For instance, the U.S. market saw the launch of Inflectra (infliximab-dyyb) in 2016 and Renflexis (infliximab-dyyb) in 2017, leading to price erosion for Remicade. Similar pressures are anticipated for other biologics as their patent exclusivity wanes.

• Generic Competition: For small molecule drugs, generic competition is a constant threat once patents expire. Imbruvica, a blockbuster drug, faces the eventual threat of generic versions, though its patent protection extends well into the future. Similarly, legacy cardiovascular drugs like Invokana have faced or will face generic entry, impacting sales volumes and pricing power.

• Rival Drug Development: Competitor companies are actively developing novel therapies in the same therapeutic areas as Janssen. For example, in oncology, companies like Bristol Myers Squibb, Merck & Co., and Roche are major competitors with extensive portfolios and R&D pipelines. In immunology, AbbVie (Humira, Skyrizi, Rinvoq) and Eli Lilly (Taltz, Olumiant) are formidable rivals.

• Pricing Pressures and Regulatory Scrutiny: Governments and healthcare payers globally are increasingly implementing measures to control drug costs. This includes price negotiations, reimbursement restrictions, and increased scrutiny of drug pricing. The U.S. Inflation Reduction Act (IRA), for instance, allows Medicare to negotiate prices for certain high-cost drugs, which could impact future revenue streams for Janssen's blockbuster medications.

• Pipeline Success Rates: The inherent risk in pharmaceutical R&D means that not all investigational drugs will successfully navigate clinical trials and gain regulatory approval. Delays or failures in the pipeline can lead to missed market opportunities and a weakened competitive position.

• M&A Activity by Competitors: Competitor companies frequently engage in mergers and acquisitions to strengthen their portfolios and R&D capabilities. This consolidation can create larger, more formidable rivals with broader market reach and resources.

What are Janssen's Strategic Imperatives for Future Growth?

Janssen's strategy for sustained growth centers on innovation, portfolio optimization, and market expansion.

• Accelerating Pipeline Progression: The primary strategic imperative is to advance its R&D pipeline, particularly in areas with high unmet needs and significant commercial potential. This involves prioritizing drug candidates with the strongest scientific rationale and market access potential. Key areas include novel oncology agents, next-generation immunology treatments, and therapies for neurodegenerative diseases. For example, ongoing research into Alzheimer's disease with lecanemab (in collaboration with Eisai) and investigational agents for other neurological conditions are critical.

• Maximizing Existing Portfolio Value: Janssen focuses on extending the lifecycle of its existing blockbuster drugs through expanded indications, combination therapies, and optimized dosing regimens. This includes leveraging real-world evidence to demonstrate product value to payers and physicians. For Darzalex, this involves exploring new combinations and earlier lines of therapy in multiple myeloma.

• Strategic Partnerships and Acquisitions: The company actively seeks external innovation through licensing agreements, collaborations, and targeted acquisitions. This approach allows Janssen to access cutting-edge technologies and promising drug candidates that complement its internal R&D efforts. Recent collaborations and acquisitions are aimed at bolstering its presence in areas like cell therapy and gene editing.

• Focus on Biologics and Advanced Therapies: Continued investment in the development and manufacturing of complex biologics, including antibody-drug conjugates (ADCs), bispecific antibodies, and cell and gene therapies, is a key strategic pillar. These modalities offer the potential for greater efficacy and targeted treatment.

• Geographic Expansion: While maintaining strength in developed markets, Janssen is pursuing growth opportunities in emerging economies. This involves tailoring market access strategies and distribution networks to meet the specific needs of these regions.

• Digital Health and Data Analytics: Integrating digital health tools and advanced data analytics into drug development, clinical trials, and patient support programs is becoming increasingly important. This enables more efficient R&D, personalized patient care, and better outcomes.

Key Takeaways

Janssen Pharmaceuticals maintains a robust market position driven by a diversified, high-revenue product portfolio in oncology, immunology, and neuroscience. Its strengths include deep R&D capabilities, substantial patent protection for key assets, and synergistic integration within Johnson & Johnson. The company's strategic focus is on advancing its innovative pipeline, maximizing the value of existing products through new indications and combinations, and pursuing strategic partnerships and acquisitions to access novel technologies. Competitive threats, including biosimilar and generic erosion, rival drug development, and pricing pressures, necessitate a proactive strategy centered on innovation and market expansion, particularly in emerging economies and through advanced therapeutic modalities like biologics and cell therapies.

FAQs

1. What is Janssen's largest revenue-generating therapeutic area? Oncology consistently represents Janssen's largest revenue-generating therapeutic area, driven by blockbuster drugs like Darzalex and Imbruvica.

2. How does Janssen address the threat of biosimilar competition for its immunology drugs? Janssen addresses biosimilar competition by focusing on the development of next-generation immunology therapies with improved efficacy and safety profiles, while also maximizing the value of its current portfolio through expanded indications and clinical evidence.

3. What are some examples of Janssen's strategic acquisitions or partnerships? Janssen has engaged in numerous strategic partnerships and acquisitions, for example, its collaboration with Legend Biotech for Carvykti (ciltacabtagene autoleucel) in multiple myeloma, and its acquisition of Momenta Pharmaceuticals to strengthen its autoimmune disease portfolio.

4. How is Janssen leveraging digital health and data analytics in its strategy? Janssen is integrating digital health tools and data analytics to enhance clinical trial efficiency, develop personalized treatment approaches, improve patient monitoring, and generate real-world evidence to support product value propositions.

5. What is the expected impact of the U.S. Inflation Reduction Act on Janssen's product portfolio? The U.S. Inflation Reduction Act allows for Medicare negotiation of prices for certain high-cost drugs, which could lead to price reductions and impact revenue for specific Janssen products subject to negotiation.

Citations

[1] Johnson & Johnson. (2024, January 23). Johnson & Johnson Announces Fourth Quarter and Full-Year 2023 Results. [Press release]. https://www.jnj.com/media/press-release/johnson-johnson-announces-fourth-quarter-and-full-year-2023-results